An integrated structure- and system-based framework to identify new targets of metabolites and known drugs

Hammad Naveed, Umar Farook Shahul Hameed, Deborah Harrus, William Bourguet, Stefan T. Arold, Xin Gao

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Motivation: The inherent promiscuity of small molecules towards protein targets impedes our understanding of healthy versus diseased metabolism. This promiscuity also poses a challenge for the pharmaceutical industry as identifying all protein targets is important to assess (side) effects and repositioning opportunities for a drug. Results: Here, we present a novel integrated structure- and system-based approach of drug-target prediction (iDTP) to enable the large-scale discovery of new targets for small molecules, such as pharmaceutical drugs, co-factors and metabolites (collectively called ‘drugs’). For a given drug, our method uses sequence order–independent structure alignment, hierarchical clustering, and probabilistic sequence similarity to construct a probabilistic pocket ensemble (PPE) that captures promiscuous structural features of different binding sites on known targets. A drug’s PPE is combined with an approximation of its delivery profile to reduce false positives. In our cross-validation study, we use iDTP to predict the known targets of eleven drugs, with 63% sensitivity and 81% specificity. We then predicted novel targets for these drugs—two that are of high pharmacological interest, the nuclear receptor PPARγ and the oncogene Bcl-2, were successfully validated through in vitro binding experiments. Our method is broadly applicable for the prediction of protein-small molecule interactions with several novel applications to biological research and drug development.
Original languageEnglish (US)
Pages (from-to)btv477
JournalBioinformatics
Volume31
Issue number24
DOIs
StatePublished - Aug 18 2015

Fingerprint Dive into the research topics of 'An integrated structure- and system-based framework to identify new targets of metabolites and known drugs'. Together they form a unique fingerprint.

Cite this